(Q26865884)

20 August 2020

angiogenesis inhibitor

1 reference

5 November 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Hyeong Gon Yu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Tien Y Wong

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Nicolas Leveziel

3

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Frank G Holz

4

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Paolo Lanzetta

7

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Youxin Chen

8

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Adnan Tufail

9

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Kyoko Ohno-Matsui

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

1 reference

March 2015

1 reference

British Journal of Ophthalmology

1 March 2015

7 references

25 April 2019

19 June 2019

25 June 2019

20 November 2019

19 August 2020

20 August 2020

5 November 2020

9 references

25 April 2019

19 June 2019

25 June 2019

20 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

19 August 2020

20 August 2020

5 November 2020

99

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

289-296

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

3

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial

10 June 2020

copyright license

7 references

25 April 2019

19 June 2019

25 June 2019

20 November 2019

19 August 2020

20 August 2020

5 November 2020

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Laser photocoagulation for choroidal neovascularisation in pathologic myopia

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Cardiac issues of noncardiac drugs: the rising story of avastin in age-related macular degeneration

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Parapapillary atrophy: histological gamma zone and delta zone

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Myopic maculopathy: a review.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Genetic factors for choroidal neovascularization associated with high myopia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Choroidal neovascularization in pathological myopia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Characterization of macular lesions in punctate inner choroidopathy with spectral domain optical coherence tomography

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Characteristic spectral-domain optical coherence tomography findings of multifocal choroiditis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Pathology of macular foveoschisis associated with degenerative myopia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Choroidal neovascularisation in pathological myopia: an update in management

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Peripheral retinal degenerations and the risk of retinal detachment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Pathologic myopia: where are we now?.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Macular hole and myopic refraction

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Natural history of choroidal neovascularization in high myopia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Prevalence of posterior vitreous detachment in high myopia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Pathologic Myopia and Choroidal Neovascularization

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Natural History of Choroidal Neovascularization in Degenerative Myopia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

Ocular risk factors for choroidal neovascularization in pathologic myopia

31 May 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Long-term pattern of progression of myopic maculopathy: a natural history study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Evaluation of pigment epithelium-derived factor and complement factor I polymorphisms as a cause of choroidal neovascularization in highly myopic eyes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Choroidal filling delay in choroidal neovascularisation due to pathological myopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Myopic choroidal neovascularization: a 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Characteristics of patients with a favorable natural course of myopic choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

photodynamic therapy for Taiwanese patients with pathologic myopia: a 2-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Intravitreal bevacizumab in myopic neovascular membranes: 24-month results

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

PHOTODYNAMIC THERAPY IN HIGHLY MYOPIC EYES WITH CHOROIDAL NEOVASCULARIZATION

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Long-Term Follow-Up of Myopic Choroidal Neovascularization Treated with Ranibizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305131

Punctate inner choroidopathy

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4345796

PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA

28 November 2018

1 reference

12 December 2020

Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series

1 reference

12 December 2020

Macular complications associated with posterior staphyloma

1 reference

12 December 2020

Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro

1 reference

12 December 2020

Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses

1 reference

12 December 2020

Vascular endothelial growth factor gene polymorphisms and choroidal neovascularization in highly myopic eyes

1 reference

12 December 2020

Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab

1 reference

12 December 2020

Visual Prognosis of Disciform Degeneration in Myopia

1 reference

12 December 2020

Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization

1 reference

12 December 2020

Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization

1 reference

12 December 2020

Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study

1 reference

12 December 2020

Myopic choroidal neovascularization

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study

1 reference

12 December 2020

Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization

1 reference

12 December 2020

Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia

1 reference

12 December 2020

A long-term study of photodynamic therapy with verteporfin for choroidal neovascularization at the edge of chorioretinal atrophy in pathologic myopia

1 reference

12 December 2020

Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia

1 reference

12 December 2020

Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment

1 reference

12 December 2020

Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia

1 reference

12 December 2020

LONG-TERM RESULTS OF PHOTODYNAMIC THERAPY FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION WITH PATHOLOGIC MYOPIA

1 reference

12 December 2020

Twofold illumination photodynamic therapy scheme for subfoveal choroidal neovascularization in pathologic myopia: results from a randomized pilot study

1 reference

12 December 2020

Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors

1 reference

12 December 2020

Photodynamic Therapy With Verteporfin for Juxtafoveal Choroidal Neovascularization in Pathologic Myopia: A Long-term Follow-up Study

1 reference

12 December 2020

10.1136/BJOPHTHALMOL-2014-305131

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24990871%20AND%20SRC:MED&resulttype=core&format=json